Summit is frank about plans for the laser vision correction company while rival VISX plays card closer to chest
This article was originally published in Clinica
Summit Technology's CEO Robert Palmisano recalls that when he joined the troubled laser vision correction company last year he did not expect a bed of roses. "And obviously I haven't found one," he told investors attending the Hambrecht & Quist Healthcare Conference this month in San Francisco.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.